NMRA vs. HALO, KRYS, CRSP, IBRX, IMVT, SWTX, ACLX, APGE, DNLI, and IOVA
Should you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Halozyme Therapeutics (HALO), Krystal Biotech (KRYS), CRISPR Therapeutics (CRSP), ImmunityBio (IBRX), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Arcellx (ACLX), Apogee Therapeutics (APGE), Denali Therapeutics (DNLI), and Iovance Biotherapeutics (IOVA). These companies are all part of the "biological products, except diagnostic" industry.
Neumora Therapeutics (NASDAQ:NMRA) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends.
Halozyme Therapeutics has higher revenue and earnings than Neumora Therapeutics.
In the previous week, Halozyme Therapeutics had 6 more articles in the media than Neumora Therapeutics. MarketBeat recorded 7 mentions for Halozyme Therapeutics and 1 mentions for Neumora Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.35 beat Neumora Therapeutics' score of 1.18 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.
47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 26.4% of Neumora Therapeutics shares are owned by insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Neumora Therapeutics presently has a consensus target price of $22.57, suggesting a potential upside of 127.99%. Halozyme Therapeutics has a consensus target price of $53.14, suggesting a potential upside of 19.99%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Halozyme Therapeutics.
Halozyme Therapeutics received 493 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Neumora Therapeutics an outperform vote while only 69.19% of users gave Halozyme Therapeutics an outperform vote.
Halozyme Therapeutics has a net margin of 36.94% compared to Neumora Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 225.71% beat Neumora Therapeutics' return on equity.
Summary
Halozyme Therapeutics beats Neumora Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Neumora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neumora Therapeutics Competitors List
Related Companies and Tools
